- Home
- EW
as 06-24-2025 4:00pm EST
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 44.8B | IPO Year: | 2000 |
| Target Price: | $80.20 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.02 | EPS Growth: | 200.69 |
| 52 Week Low/High: | $58.93 - $95.25 | Next Earning Date: | 07-23-2025 |
| Revenue: | $5,522,300,000 | Revenue Growth: | 8.23% |
| Revenue Growth (this year): | 11.81% | Revenue Growth (next year): | 9.54% |
Stock Insider Trading Activity of Edwards Lifesciences Corporation (EW)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chopra Daveen | EW | CVP, TMTT | May 22 '25 | Sell | $75.08 | 1,500 | $112,612.50 | 33,496 | |
| Ullem Scott B. | EW | CVP, Chief Financial Officer | May 7 '25 | Sell | $74.40 | 11,250 | $837,034.88 | 41,098 |
Latest Edwards Lifesciences Corporation News
EW Breaking Stock News: Dive into EW Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Jefferies Adjusts Price Target on Edwards Lifesciences to $77 From $73
Simply Wall St.
7 days ago
3 Undervalued Asian Small Caps With Insider Buying
Zacks
8 days ago
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
MT Newswires
8 days ago
Edwards Lifesciences Insider Sold Shares Worth $673,268, According to a Recent SEC Filing
Argus Research
14 days ago
EW: Lowering target price to $80.00
MT Newswires
23 days ago
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating
Zacks
a month ago
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
MT Newswires
a month ago
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating
Compare EW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EW Edwards Lifesciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.